Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-09-10
1998-05-26
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, 514921, 530324, 530350, 530829, 424529, 424534, A61K 3800, A61K 3514
Patent
active
057564647
ABSTRACT:
Methods and materials for the treatment of humans suffering from hemorrhage due to trauma are provided, in which therapeutically effective amounts of BPI protein products are administered.
REFERENCES:
patent: 5089274 (1992-02-01), Marra et al.
patent: 5171739 (1992-12-01), Scott et al.
patent: 5198541 (1993-03-01), Elsbach et al.
patent: 5234912 (1993-08-01), Marra et al.
patent: 5245013 (1993-09-01), Ulevitch et al.
patent: 5308834 (1994-05-01), Scott et al.
patent: 5334584 (1994-08-01), Scott et al.
patent: 5348942 (1994-09-01), Little, II et al.
patent: 5420019 (1995-05-01), Theofan et al.
patent: 5439807 (1995-08-01), Grinna
patent: 5447913 (1995-09-01), Ammons et al.
patent: 5466580 (1995-11-01), White et al.
patent: 5466581 (1995-11-01), White et al.
patent: 5484705 (1996-01-01), White et al.
patent: 5488034 (1996-01-01), McGregor et al.
patent: 5494896 (1996-02-01), Hansbrough
patent: 5523288 (1996-06-01), Cohen et al.
patent: 5532216 (1996-07-01), Espevik et al.
patent: 5576292 (1996-11-01), Elsbach et al.
patent: 5578568 (1996-11-01), Ammons et al.
patent: 5578572 (1996-11-01), Horwitz et al.
Abraham and Raffin, "Sepsis Therapy Trials: Continued Disappointment or Reason for Hope?" JAMA, 271(23):1876-1878 (Jun. 15, 1994).
ACCP/SCCM Consensus Conference Committee, "American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use or innovative therapies in sepsis," Crit. Care Med., 20(6):864-874 (Jun., 1992).
Adjei and Garren, "Pulmonary Delivery of Peptide Drugs: Effect of Particle Size on Bioavailability of Leuprolide Acetate in Healthy Male Volunteers," Pharmaceutical Research, 7(6):565-569 (1990).
Agarwal et al., "Blood Transfusion Increases the Risk of Infection After Trauma," Arch. Surg., 128:171-177 (Feb., 1993).
Ammons et al., "Recombinant Amino Terminal Fragment of Bactericidal/Permeability Increasing Protein Prevents Hemodynamic Responses to Endotoxin," Circulatory Shock, 41(3):176-184 (Nov., 1993).
Ammons et al., "Protective Effects of an N-Terminal Fragment of Bactericidal/Permeability-Increasing Protein in Rodent Models of Gram-Negative Sepsis: Role of Bactericidal Properties," J. Infect. Dis., 170(6):1473-82 (Dec. 1994).
Ammons et al., "An N-Terminal Fragment of Bactericidal/Permeability-Increasing Protein Protects against Hemodynamic and Metabolic Derangements in Rat Gram-Negative Sepsis," J. Endotoxin Res., 3(1):57-66 (1996).
Ammons et al., "Protective Effects of an N-Terminal Fragment of Bactericidal/Permeability-Increasing Protein in Endotoxemia and Gram-Negative Sepsis," Novel Therapeutics Strategies in the Treatment of Sepsis, pp. 55-70 (1996).
Baggiolini et al., "Neutrophil-activating Peptide-1/Interleukin 8, a Novel Cytokine That Activates Neutrophils," J. Clin. Invest., 84:1045-1049 (Oct., 1989).
Bahrami et al., "Endotoxemia in Rats Subjected to the Hemorrhage: Effects of Bacteriocidal/Permeability Increasing Protein (BPI)," presentation at Vienna International Endotoxin Society Meeting, 1 page (Aug., 1992).
Barron, "Clinical Frontiers: Pathophysiology of Septic Shock and Implications for Therapy," Clinical Pharmacy, 12(11):829-845 (Nov., 1993).
Berg, R. D., "Bacterial Translocation From The Gastrointestinal Tract,"J. of Medicine, 23(3 & 4):217-244 (1992).
Berry, L. J. (Ed.), "Cellular Biology of Endotoxin," Handbook of Endotoxin, vol. , Elsevier, New York, pp. xvii-xxi (1985).
Bickell et al., "Immediate Versus Delayed Fluid Resuscitation for Hypotensive Patients With Penetrating Torso Injuries," New Engl. J. Med., 331(17):1101-1109 (Oct. 27, 1994).
Bigatello et al., "Endotoxemia, Encephalopathy, and Mortality in Cirrhotic Patients," Amer. J. Gastroenterology, 82(1)L11-15 (1987).
Binnema et al., "Quantitation of Urokinase Antigen in Plasma and Culture Media by Use of an Elisa," Throm. Res., 43:569-577 (1986).
Bloom et al., "Serum Neopterin Levels Following Intravenous Endotoxin Administration to Normal Humans," Immunobiol., 181:317-323 (1990).
Boermeester et al., "Bactericidal/permeability-increasing protein (BPI) prevents hemodynamic and metabolic derangements following partial hepatectomy," presented at Dutch Society of Gastroenterology Meeting, p. 84 (Oct. 7, 1993) (Abstract).
Boermeester et al., "A Prophylactic Approach towards Postoperative Endotoxemia," Yearbook of Intensive Care and Emergency Medicine 1994, Vincent, J. L., (Ed.), Springer-Verlag, New York, pp. 35-41 (1994).
Boermeester et al., "Endotoxin and Interleukin-1 Related Hepatic Inflammatory Response Promotes Liver Failure After Partial Hepatectomy," Hepatology, 22:1499-1506 (1995).
Boermeester et al., "Liver Failure Induces a Systemic Inflammatory Response," Amer. J. Pathology, 147(5):1428-1440 (Nov., 1995).
Bone et al., "Definitions for Sepsis and Organ Failure," Critical Care Medicine, 20(6):724-726 (1992).
Boujoukos et al., "Detection of Interleukin-8 in Bronchoalveolar Lavage Without Alveolar Neutrophil Influx, Before and After Intravenous Endotoxin in Normal Humans," Am. Rev. Resp. Dis.,145(4):A441 (Apr., 1992) (Abstract).
Boujoukos et al., "Compartmentalization of the Acute Cytokine Response in Humans After Intravenous Endotoxin Administration," J. Appl. Physiol. 74:3027-3033 (1993).
Bradley et al., "Hemodynamic Alterations in Normotensive and Hypertensive Subjects During the Pyrogenic Reaction,"J. Clin. Invest., 24:749-758 (1945).
Brathwaite et al., "Bacterial Translocation Occurs in Humans After Traumatic Injury: Evidence Using Immunofluorescence," J. Trauma, 34(4):586-590 (1993).
Braunwald et al., Heart Disease, The Textbook of Cardiovascular Medicine, 3rd Edition, Braunwald, E., (Ed.), W.B. Saunders Company, Harcourt Brace Jovanich, Inc., Philadelphia, PA, p. 12 (1988).
Brigham et al., "Endotoxin and Lung Injury," Rev. Respir. Dis., 133:913-927 (1986).
Calandra et al., "Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-1, Interferon-.alpha., and Interferon-.mu. in the Seurm of Patients with Septic Shock," J. Infectious Diseases, 161:982-987 (1990).
Calandra et al., "High Circulating Levels of Interleukin-6 in Patients with Septic Shock: Evolution During Sepsis, Prognostic Value, and Interplay with Other Cytokines," Am. J. Medicine, 91:23-29 (Jul. 1991).
Canon et al., "Circulating Interleukin 1 and Tumor Necrosis Factor in Septic Shock and Experimental Endotoxin Fever,"J. Infection Diseases, 161:79-84 (1990).
Captopril-Digoxin Multicenter Research Group, "Comparative Effects of Therapy With Captopril and Digoxin in Patients With Mild to Moderate Heart Failure," JAMA, 259(4):539-544 (Jan. 22/29 1988).
Carrico et al., "What's New in Trauma and Burns," Bulletin of the American College of Surgeons 80(1)71-74 (1995).
Cavaillon, J. M., "Controversies Surrounding Current Therapies For Sepsis Syndrome," Bull. Inst. Pasteur., 93:21-41 (1995).
Champion et al., "Trauma Score," Crit. Care Med., 9(9):672-676 (Sep., 1981).
Chimielewska et al., "Evidence for a Rapid Inhibitor Tissue Plasminogen Activator in Plasma," Thromb. Res., 31:427-436 (1983).
Cochrane, "The Enhancement of Inflammatory Injury," Am. Rev. Respir. Dis., 136:1-2 (1980).
Colman, "Surface-mediated Defense Reactions, The Plasma Contact Activation System," J. Clin. Invest., 73:1249-1253 (May 1984).
Cross, A.S., "Antiendotoxin Antibodies: A Dead End?" Annals of Internal Medicine, 121(1):58-60 (Jul. 1, 1994).
Danner et al., "Endotoxemia in Human Septic Shock," Chest, 99:169-175 (Jan., 1991).
Deitch, E.A., "The Role of Intestinal Barrier Failure and Bacterial Translocation in the Development of Systemic Infection and Multiple Organ Failure," Arch Surg 125:403-404 (Mar., 1990).
Deitch, E.A., "Multiple Organ Failure: Pathophysiology and Potential Future Therapy," Ann. Surg., pp. 117-134 (Aug., 1992).
DeLa Cadena et al., "Activation of the Kallikrein-Xn System After Endotoxin Administration to Normal Human Volunteers," Blood, 81(12):3313-3317 (Jun. 15, 1993).
Dinarello, "The Proinflammatory Cytokines Interleukin-1 and Tumor Necrosis Factor and Treatment of the Septic Shock Syndrome," J. Infection Diseases, 163:117-1184
Scannon Patrick J.
Wedel Nancy
Mohamed Abdel A.
Tsang Cecilia J.
Xoma Corporation
LandOfFree
Therapeutic uses of BPI protein products in humans with hemmorha does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic uses of BPI protein products in humans with hemmorha, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic uses of BPI protein products in humans with hemmorha will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1960099